Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHuEpo on Platelet Function in Healthy Subjects
NCT00368238Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2005
- Countries
- 1
- Sponsor
- Yale University
- Modality
- Biologic, rProtein (Recombinant Protein)
- Drugs
- epoetin alfa
- Conditions
- myocardial infarction (MI)
01
Overview
Phase 2, randomised, double-blind trial of epoetin alfa in myocardial infarction (MI) (4 arms), sponsored by Yale University. Primary endpoints: Bleeding time and Platelet function assay closure time. Started Oct 2005; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
rHuEpo 100 U/kg
rHuEpo 100 U/kg daily + Aspirin + Clopidogrel
rHuEpo 200 U/kg
rHuEpo 200 U/kg daily + Aspirin + Clopidogrel
rHuEpo 400 U/kg
rHuEpo 400 U/kg daily + Aspirin + Clopidogrel
Placebo
Placebo + Aspirin + Clopidogrel
03
Endpoints
Primary
Bleeding time
Platelet function assay closure time
Secondary
Complete Blood Count
Prothrombin Time
Partial Thromboplastin Time
P-selectin
von Willebrand factor
Beyond the preview
Go deeper on NCT00368238.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368238.